QRxPharmareported today positive outcomes of its European Scientific Advice meetings on the development and registration of MoxDuo IR, an immediate release Dual-Opioid™ pain therapy. The Company is currently completing pivotal Phase 3 trials required for filing a New Drug Application (NDA) for MoxDuo IR with the United States Food and Drug Administration (FDA).

• Previous Entry: Canon’s second quarterly profit quadruples on global demand for cameras, office equipment
• Next Entry: First step toward electronic DNA sequencing: Translocation through graphene nanopores